The Federal Circuit has recently provided significant relief to the legal community by determining that patent claims licensed by Allergan were not invalid due to obviousness-type double patenting. This decision has assuaged fears among attorneys who were concerned that the court’s stance might simplify the invalidation of patents that extended their expiration dates due to regulatory delays. For more detailed information, you can read the original article here.